Thomas J. Schall - 11 Jun 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 17:37:43 UTC
Prior SEC filing: 20 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall

Key filing fact

Thomas J. Schall filed Form 4 for Immuneering Corp (IMRX) on 11 Jun 2026.

Key facts

This page summarizes Thomas J. Schall's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 17:37.

Change

Previous filing in this sequence was filed on 20 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001423084 Primary reporting owner

Schall Thomas J.

Relationship: Director
Address: C/O IMMUNEERING CORPORATION, 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value
Shares: +33,350
Change %
Price: $0.000000^*
Shares after: 33,350
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 33,350
Exercise price: $4.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.